MACROGENICS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:
| MacroGenics, Inc. | |
| By: | /s/ Eric Risser |
| Eric Risser | |
| President and CEO and Director |
Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Eric Risser | President and CEO and Director(Principal Executive Officer) | March 9, 2026 |
| Eric Risser | ||
| /s/ James Karrels | Senior Vice President and Chief Financial Officer (Principal Financial Officer) | March 9, 2026 |
| James Karrels | ||
| /s/ Beth Smith | Vice President, Controller and Treasurer(Principal Accounting Officer) | March 9, 2026 |
| Beth Smith | ||
| /s/ Karen Ferrante, M.D. | Director | March 9, 2026 |
| Karen Ferrante, M.D. | ||
| /s/ William Heiden | Director | March 9, 2026 |
| William Heiden | ||
| /s/ Edward Hurwitz | Director | March 9, 2026 |
| Edward Hurwitz | ||
| /s/ Scott Jackson | Director | March 9, 2026 |
| Scott Jackson | ||
| /s/ Meenu Chhabra Karson | Director | March 9, 2026 |
| Meenu Chhabra Karson | ||
| /s/ Scott Koenig, M.D., Ph.D. | Director | March 9, 2026 |
| Scott Koenig, M.D., Ph.D. | ||
| /s/ Margaret A. Liu, M.D. | Director | March 9, 2026 |
| Margaret A. Liu, M.D. | ||
| /s/ Federica O’Brien | Director | March 9, 2026 |
| Federica O’Brien | ||
| /s/ Jay Siegel, M.D. | Director | March 9, 2026 |
| Jay Siegel, M.D. | ||
| /s/ David Stump, M.D. | Director | March 9, 2026 |
| David Stump, M.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| PageNumber | |
| Report of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42) | F - 1 |
|---|---|
| Consolidated Balance Sheets at December 31, 2025 and December 31, 2024 | F - 3 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | F - 4 |
| Consolidated Statements of Stockholders' Equity for the years ended December 31, 2025, 2024 and 2023 | F - 5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | F - 6 |
| Notes to Consolidated Financial Statements | F - 7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.